http://rdf.ncbi.nlm.nih.gov/pubchem/patent/GB-1226743-A
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCAdditional | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18551 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2039-5252 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2770-36234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18534 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16251 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-18634 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16234 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16151 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2760-16134 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-145 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K39-12 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N7-00 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-20 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-12 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-155 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K39-145 |
| filingDate | 1967-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 1971-03-31-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | GB-1226743-A |
| abstract | 1,226,743. Viral vaccines. WELLCOME FOUNDATION Ltd. 9 April, 1968 [19 April, 1967], No. 17976/67. Heading A5B. Animal RNA viruses having a helical core and being viruses of the myxovirus e.g. Myxovirus influenzae-A, influenzae-B or paramyxovirus group e.g. Myxovirus parainfluenzae-3 or Simian virus-5 or the respiratory syncytial virus or rubella virus are purified or concentrated by precipitating the virus from an aqueous suspension thereof by adding to said suspension a water-soluble polyalkylene glycol and an electrolyte solution having a concentration of 0.15N in a neutral medium of pH 6.5 to 7.5 and separating the sediment containing the virus. The polyalkylene glycol may be polyethylene glycol of the formula H(OCH 2 CH 2 ) n OH where n is from 80 to 180 e.g. polyethylene glycol 6000, and the electrolyte is preferably NaCl. The precipitation is preferably carried out at pH 7.4 with a concentration of polyethylene glycol of 7.5% w/v. The suspension of the virus may be allowed to stand at 4C for about an hour after the treatment with the polyalkylene glycol and is subsequently subjected to centrifugation at 2,000 to 10,000g for about 20 mins. or at 12,000g at a continuous flow rate of 50 to 100 ml per min. The sediment may be resuspended in a citric saline buffer optionally containing sucrose, phosphate-buffered saline solution or medium S.M. 199. Vaccines may be produced by inactivation of the virus. |
| isCitedBy | http://rdf.ncbi.nlm.nih.gov/pubchem/patent/EP-0043272-A1 http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-5071758-A http://rdf.ncbi.nlm.nih.gov/pubchem/patent/US-4517304-A |
| priorityDate | 1967-04-19-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 37.